NCT00517517已完成1 期
An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 110
- 试验地点
- 6
- 主要终点
- Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by Microneutralization (MN) test >= 1:20
研究概览
简要总结
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population. Subjects will be randomized 1:1 to receive two intramuscular injections (21 days apart) of the vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation. Subjects will be monitored for safety and for antibody response to the vaccine. A data safety monitoring board will review the safety data after the first and second vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are 21 to 45 years of age, inclusive, on the day of screening
- •Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry
- •Are clinically healthy, as determined by the Investigator's clinical judgment through collection of medical history and performance of a physical examination
- •Are physically and mentally capable of participating in the study
- •Agree to keep a daily record of symptoms for the duration of the study
- •If female and capable of bearing children, have a negative urine pregnancy test result within 24 hours of the scheduled first vaccination and agree to employ adequate birth control measures for the duration of the study.
排除标准
- •Have a history of exposure to H5N1 virus or a history of vaccination with an H5N1 influenza virus
- •Are at high risk of contracting H5N1 influenza infection (e.g. poultry workers)
- •Suffer from or have a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder
- •Suffer from any inherited or acquired immunodeficiency
- •Test positive for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HbsAg) or Hepatitis C Virus (HCV)
- •Suffer from a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (>800µg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs
- •Have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré syndrome)
- •Have a history of severe allergic reactions or anaphylaxis
- •Have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating
- •Have received a blood transfusion or immunoglobulins within 90 days of study entry
- •Have donated blood or plasma within 30 days of study entry
- •Have received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study
- •Have undergone systemic corticoid therapy within 30 days prior to study entry
- •Have a functional or surgical asplenia
- •Have a known or suspected problem with alcohol or drug abuse
- •Were administered an investigational drug within six weeks prior to study entry or are concurrently participating in a clinical study that includes the administration of an investigational product
- •Are a member of the team conducting this study or are in a dependent relationship with the study Investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site conducting the study
- •If female: are pregnant or lactating
结局指标
主要结局
Number of subjects with antibody response to the vaccine strain associated with protection 21 days after the second vaccination defined as titer measured by Microneutralization (MN) test >= 1:20
时间窗: 21 days after the second vaccination (= Day 42 in the study)
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsInfluenzaNCT05606965ModernaTX, Inc.172
已完成
1 期
A/H1N1 Immunogenicity and Safety in AdultsPandemic InfluenzaInfluenzaNCT00959465Resilience Government Services, Inc.408
终止
1 期
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) ParticipantsBladder CancerNCT02792192Hoffmann-La Roche24
尚未招募
1 期
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3Human Papillomavirus Associated Intraepithelial NeoplasiaCervical Intraepithelial Neoplasia Grade 2/3Human Papillomavirus Type 16 InfectionHuman Papillomavirus Type 18 InfectionNCT06273553RinuaGene Biotechnology Co., Ltd.39
已完成
1 期
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza VirusHealthyNCT01405885Inovio Pharmaceuticals116